Moderna, Bird Flu

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
Cryptocurrencies pulled back after President Trump's inauguration address, in which he didn't mention crypto. That weighed on shares of MicroStrategy, the software company-turned-bitcoin buyer, in ...
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.
CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or ...
The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.